Comparison
Abacavir Hypersensitivity C5768819 vs 3 Methylglutaconic Aciduria Type 1 C0342727
Clinical comparison between Abacavir Hypersensitivity and 3 Methylglutaconic Aciduria Type 1 for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
3 Methylglutaconic Aciduria Type 1 C0342727
A rare inherited metabolic disorder affecting how the body processes certain proteins. It can cause neurological problems, delayed development, and metabolic imbalances. Management focuses on specialized diet and supportive care.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
3 Methylglutaconic Aciduria Type 1 C0342727
0-null
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
3 Methylglutaconic Aciduria Type 1 C0342727
moderate
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
3 Methylglutaconic Aciduria Type 1 C0342727
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
3 Methylglutaconic Aciduria Type 1 C0342727
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
3 Methylglutaconic Aciduria Type 1 C0342727
metabolic
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
3 Methylglutaconic Aciduria Type 1 C0342727
metabolic
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 3-methylglutaconic-aciduria-type-1-C0342727 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 3 Methylglutaconic Aciduria Type 1 C0342727 | Discriminating power |
|---|---|---|---|
| Timing | Often acute after abacavir exposure; exact timing varies. | Chronic inherited course, often early but variable; supplied onset data are incomplete. | High |
| Cause | Linked to abacavir and immune risk, including HLA-B*5701. | Inborn metabolic disorder, not triggered by abacavir. | High |
| Clinical pattern | May include fever, rash, or systemic symptoms; none is definitive alone. | May include developmental delay, neurologic problems, or metabolic imbalance. | Moderate |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
Illness begins after starting abacavir
Recent drug exposure with compatible symptoms raises concern for hypersensitivity.
High
HLA-B*5701 is positive before treatment
This marker identifies higher risk; abacavir is generally avoided.
High
Symptoms improve after abacavir is stopped
The time course supports a drug reaction, but confirmation is clinical.
Moderate
Choose 3 Methylglutaconic Aciduria Type 1 C0342727 when
Persistent developmental or neurologic concerns
A chronic metabolic disorder fits better than an acute drug reaction.
Moderate
Abnormal urine organic-acid result
3-methylglutaconic acid may suggest the disorder but is not a diagnosis by itself.
High
Early-life or familial metabolic illness
An inherited course is more consistent and may need genetic confirmation.
Moderate
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 3 Methylglutaconic Aciduria Type 1 C0342727 | Interpretation |
|---|---|---|---|
| HLA-B*5701 | Used before abacavir to estimate hypersensitivity risk. | Not diagnostic for this metabolic disorder. | A risk marker, not proof of an active reaction. |
| Urine organic acids | Not the primary test for abacavir hypersensitivity. | May show 3-methylglutaconic acid; no universal cutoff is established here. | An abnormal result requires specialist interpretation and is not automatically diagnostic. |
| Drug and symptom timeline | Recent abacavir exposure is central. | Course is independent of abacavir. | History often distinguishes the conditions while confirmatory tests are arranged. |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- Often improves after abacavir is stopped, although severe reactions can occur; exact outcomes vary.
- Factors
- Recognition speed, avoidance of rechallenge, and overall clinical status.
3 Methylglutaconic Aciduria Type 1 C0342727
- Outcome
- Chronic and variable; neurologic or developmental effects may persist.
- Factors
- Symptom severity, metabolic stability, supportive care, and individual course.
Time frame: Days to weeks for the drug reaction; lifelong for the metabolic disorder.
Early recognition and specialist care matter, but the prognoses are not directly comparable.
Complications comparison
| Complication | Presentation |
|---|---|
| Severe systemic reaction | Can become serious and may recur if abacavir is restarted. Not a typical feature of this metabolic disorder. Do not restart abacavir after suspected hypersensitivity unless a specialist directs it. |
| Neurologic impairment | Not the defining complication. Developmental or neurologic problems may occur with variable severity. Outcomes are not uniform and cannot be predicted from sparse data. |
| Metabolic imbalance | Not the primary mechanism. Illness or reduced intake may worsen metabolic imbalance. Management is individualized; no universal threshold is established here. |
Patient education highlights
- HighAbacavir safety
Report fever, rash, or systemic symptoms promptly. Do not restart abacavir after suspected hypersensitivity unless directed.
- HighTest meaning
HLA-B*5701 estimates drug risk. Organic-acid or genetic results need clinician interpretation and are not diagnoses alone.
- MediumDifferent conditions
One is an acute drug-related immune reaction; the other is a rare chronic inherited metabolic disorder.